Ovarian Cancer Recurrent
1 competing product in clinical development for Ovarian Cancer Recurrent.
Pipeline by Phase
Phase 1/21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |